PMID: 8584315Oct 1, 1995Paper

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents

The Pediatric Infectious Disease Journal
D A ClementsC M Wilfert

Abstract

A total of 465 healthy infants and adolescents ages 12 months to 17 years without a known history of varicella or recent exposure to varicella-zoster virus VZV were immunized with live attenuated Oka/Merck varicella vaccine from November, 1984, through April, 1989. The vaccine administered was from 1 of 7 production lots containing from 950 to 3265 plaque-forming units and was well-tolerated with few side effects. The seroconversion rate for seronegative subjects was 94.6% (403 of 426). This varied by lot from 85% (950 plaque-forming units) to 100% (3010 and 3265 plaque-forming units). Breakthrough disease after exposure to varicella in seroconverters during 5 to 10 years of follow-up was 18.6% (75 of 403). The breakthrough disease was characterized by a maculopapular rash with a median of 35 lesions, most of which were macules. Breakthrough disease lasted a median of 5 days and the median temperature was 99 degrees F; 65.3% (49 of 75) of subjects were afebrile and 2.7% (2 of 75) of subjects had temperatures of > 102.9 degrees F. Varicella vaccine provides excellent (94.6%) seroconversion, and most children who developed breakthrough disease (18.6%) experienced a modified, milder form of illness than has been observed with natu...Continue Reading

Citations

Aug 10, 2000·Journal of Medical Virology·K TeradaT Sadahiro
Mar 23, 2004·Journal of the American Academy of Dermatology·Jashin J WuStephen K Tyring
Apr 13, 2000·Pediatric Clinics of North America·S A Chartrand
Apr 9, 1999·Vaccine·J Díez DomingoA Morant
Oct 23, 2012·Cardiology in the Young·Kiyoshi OgawaKenji Hoshino
Mar 7, 1998·The New England Journal of Medicine·R W Spingarn, J A Benjamin
Mar 29, 2001·The New England Journal of Medicine·M VázquezE D Shapiro
Dec 13, 2002·The New England Journal of Medicine·Karin GalilJane Seward
Mar 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael RothbergJohn B Wong
Dec 23, 1999·The Pediatric Infectious Disease Journal·D A ClementsE B Walter
Feb 15, 2001·The Pediatric Infectious Disease Journal·S A Plotkin
Feb 12, 2004·The Pediatric Infectious Disease Journal·Barbara KuterUNKNOWN Study Group for Varivax
May 8, 2004·The Pediatric Infectious Disease Journal·Bernard RentierUNKNOWN European Working Group on Varicella
Jan 10, 2006·Journal of Paediatrics and Child Health·A R FrydenbergJ Royle
Jan 18, 2005·Clinical Microbiology Reviews·Sophie Hambleton, Anne A Gershon
May 14, 2010·Clinical and Vaccine Immunology : CVI·Stanley A Plotkin
May 14, 2003·Journal of Virology·Dennis M WallingPaul D Ling
Jan 1, 1996·Annual Review of Microbiology·A M Arvin, A A Gershon
Jun 11, 2010·Journal of Medical Case Reports·Vasilios TzilasGeorgios Tsoukalas
Feb 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Krow AmpofoAnne Gershon
Mar 5, 2004·Expert Opinion on Biological Therapy·Michiaki Takahashi
Nov 29, 2002·Pediatric Annals·Philip LaRussa
Sep 22, 2012·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K M Posfay-BarbeC A Siegrist
Apr 1, 1996·Current Problems in Pediatrics·P D ReumanE M Ayoub
Apr 17, 2001·Infectious Disease Clinics of North America·A A Gershon
Jul 9, 2002·The Journal of Infection·W J Edmunds, M Brisson
Jul 9, 2002·The Journal of Infection·Barbara Watson
May 12, 2016·Annual Review of Immunology·Akiko Iwasaki
Jan 31, 2017·Immunological Reviews·Georgia D Tomaras, Stanley A Plotkin
Jun 24, 2014·The Cochrane Database of Systematic Reviews·Kristine MacartneyPeter McIntyre
Mar 11, 2005·Expert Review of Anti-infective Therapy·Barbara Watson
Sep 1, 1996·Reviews in Medical Virology·G P Garnett, N M Ferguson
Jul 11, 2013·The Pediatric Infectious Disease Journal·Paolo BonanniPeter Wutzler
Sep 20, 2010·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada·Ben TanUNKNOWN approved by NACI.

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.